Đang chuẩn bị liên kết để tải về tài liệu:
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive nonsmall cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. |

TÀI LIỆU LIÊN QUAN

TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An openlabel, phase I trial with an extensive biomarker program

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial